These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20362020)

  • 1. Downregulation of EGFR by a novel multivalent nanobody-liposome platform.
    Oliveira S; Schiffelers RM; van der Veeken J; van der Meel R; Vongpromek R; van Bergen En Henegouwen PM; Storm G; Roovers RC
    J Control Release; 2010 Jul; 145(2):165-75. PubMed ID: 20362020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
    Pedersen MW; Jacobsen HJ; Koefoed K; Hey A; Pyke C; Haurum JS; Kragh M
    Cancer Res; 2010 Jan; 70(2):588-97. PubMed ID: 20068188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment.
    van der Meel R; Oliveira S; Altintas I; Haselberg R; van der Veeken J; Roovers RC; van Bergen en Henegouwen PM; Storm G; Hennink WE; Schiffelers RM; Kok RJ
    J Control Release; 2012 Apr; 159(2):281-9. PubMed ID: 22227023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
    Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
    Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.
    Lammerts van Bueren JJ; Bleeker WK; B√łgh HO; Houtkamp M; Schuurman J; van de Winkel JG; Parren PW
    Cancer Res; 2006 Aug; 66(15):7630-8. PubMed ID: 16885363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting.
    Jaramillo ML; Leon Z; Grothe S; Paul-Roc B; Abulrob A; O'Connor McCourt M
    Exp Cell Res; 2006 Sep; 312(15):2778-90. PubMed ID: 16806168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.
    Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C
    Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
    Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M
    Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.
    Thomas SM; Bhola NE; Zhang Q; Contrucci SC; Wentzel AL; Freilino ML; Gooding WE; Siegfried JM; Chan DC; Grandis JR
    Cancer Res; 2006 Dec; 66(24):11831-9. PubMed ID: 17178880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy.
    Hambek M; Solbach C; Schnuerch HG; Roller M; Stegmueller M; Sterner-Kock A; Kiefer J; Knecht R
    Cancer Res; 2001 Feb; 61(3):1045-9. PubMed ID: 11221831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.
    Altintas I; Heukers R; van der Meel R; Lacombe M; Amidi M; van Bergen En Henegouwen PM; Hennink WE; Schiffelers RM; Kok RJ
    J Control Release; 2013 Jan; 165(2):110-8. PubMed ID: 23159529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
    Fan Z; Masui H; Altas I; Mendelsohn J
    Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
    O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA
    Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amlodipine, a Ca2+ channel blocker, suppresses phosphorylation of epidermal growth factor receptor in human epidermoid carcinoma A431 cells.
    Yoshida J; Ishibashi T; Yang M; Nishio M
    Life Sci; 2010 Jan; 86(3-4):124-32. PubMed ID: 19951711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.